Search research articles
Contact Us
Filters
Showing results (71-80 of 334) with videos related to
Page
of 34
Sort By:
Annals of the Rheumatic Diseases
|
May 27, 2011
Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study
Gerd R Burmester, Eugen Feist, Matthew A Sleeman, et al.
Arthritis Research & Therapy
|
April 25, 2007
Treatment of posttraumatic and focal osteoarthritic cartilage defects of the knee with autologous polymer-based three-dimensional chondrocyte grafts: 2-year clinical results
Christian Ossendorf, Christian Kaps, Peter C Kreuz, et al.
Clinical Rheumatology
|
May 20, 2023
Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial
Eric L Matteson, Martin Aringer, Gerd R Burmester, et al.
Journal of Clinical Medicine
|
October 13, 2021
Distinct Effects of Interleukin-1β Inhibition upon Cytokine Profile in Patients with Adult-Onset Still's Disease and Active Articular Manifestation Responding to Canakinumab
Khetam Ghannam, Jan Zernicke, Claudia Kedor, et al.
Immunobiology
|
February 28, 2003
Casein is an essential cofactor in autoantibody reactivity directed against the C-terminal SmD1 peptide AA 83-119 in systemic lupus erythematosus
Gabriela Riemekasten, Jeannette Marell, Christian Hentschel, et al.
Annals of the Rheumatic Diseases
|
May 8, 2012
Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
Gerd R Burmester, Remo Panaccione, Kenneth B Gordon, et al.
Arthritis Research & Therapy
|
April 25, 2006
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
Thomas Dörner, Joerg Kaufmann, William A Wegener, et al.
Arthritis Research & Therapy
|
February 14, 2006
Detailed analysis of the variability of peptidylarginine deiminase type 4 in German patients with rheumatoid arthritis: a case-control study
Berthold Hoppe, Thomas Häupl, Rudolf Gruber, et al.
RMD Open
|
January 4, 2023
Mild COVID-19 despite inadequate antibody response after repeated vaccinations in rheumatic disease patients with rituximab-induced B cell depletion: a case series
Alexander Ten Hagen, Elisa Habermann, Sandra Hermann, et al.
Annals of the Rheumatic Diseases
|
December 29, 2010
Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)
Gerd R Burmester, E Feist, H Kellner, et al.
Page
of 34
Search research articles
Search
Showing results (71-80 of 334) with videos related to
Sort By:
Page
of 34
Annals of the Rheumatic Diseases
|
May 27, 2011
Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study
Gerd R Burmester, Eugen Feist, Matthew A Sleeman, et al.
Arthritis Research & Therapy
|
April 25, 2007
Treatment of posttraumatic and focal osteoarthritic cartilage defects of the knee with autologous polymer-based three-dimensional chondrocyte grafts: 2-year clinical results
Christian Ossendorf, Christian Kaps, Peter C Kreuz, et al.
Clinical Rheumatology
|
May 20, 2023
Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial
Eric L Matteson, Martin Aringer, Gerd R Burmester, et al.
Journal of Clinical Medicine
|
October 13, 2021
Distinct Effects of Interleukin-1β Inhibition upon Cytokine Profile in Patients with Adult-Onset Still's Disease and Active Articular Manifestation Responding to Canakinumab
Khetam Ghannam, Jan Zernicke, Claudia Kedor, et al.
Immunobiology
|
February 28, 2003
Casein is an essential cofactor in autoantibody reactivity directed against the C-terminal SmD1 peptide AA 83-119 in systemic lupus erythematosus
Gabriela Riemekasten, Jeannette Marell, Christian Hentschel, et al.
Annals of the Rheumatic Diseases
|
May 8, 2012
Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
Gerd R Burmester, Remo Panaccione, Kenneth B Gordon, et al.
Arthritis Research & Therapy
|
April 25, 2006
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
Thomas Dörner, Joerg Kaufmann, William A Wegener, et al.
Arthritis Research & Therapy
|
February 14, 2006
Detailed analysis of the variability of peptidylarginine deiminase type 4 in German patients with rheumatoid arthritis: a case-control study
Berthold Hoppe, Thomas Häupl, Rudolf Gruber, et al.
RMD Open
|
January 4, 2023
Mild COVID-19 despite inadequate antibody response after repeated vaccinations in rheumatic disease patients with rituximab-induced B cell depletion: a case series
Alexander Ten Hagen, Elisa Habermann, Sandra Hermann, et al.
Annals of the Rheumatic Diseases
|
December 29, 2010
Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)
Gerd R Burmester, E Feist, H Kellner, et al.
Page
of 34